Latest Intellectual Property News

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Control Bionics Limited is set to acquire the remaining stake in Neuro Elite Athletics, integrating the NeuroBounce athletic performance program with its EMG technology to accelerate growth in key markets.

IMDEX has announced the acquisition of Advanced Logic Technology (ALT) and Mount Sopris Instruments (MSI), broadening its portfolio in downhole sensing and geoscience software with expected earnings accretion in FY26.

IMDEX Limited is set to acquire Advanced Logic Technology and Mount Sopris Instruments for nearly A$99 million upfront, significantly boosting its earth science sensor and software capabilities. The deal integrates industry-leading technologies and software, promising to accelerate IMDEX’s subsurface intelligence platform and market reach.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.

Hancock & Gore is rebranding as Schoolblazer Limited following its acquisition of Trutex, consolidating its global school uniform operations and targeting over $200 million in revenue by FY27.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

White Energy Company Limited has launched a 5-for-12 partially underwritten entitlement offer at $0.027 per share, aiming to raise approximately $3.5 million to fund mineral exploration and corporate needs. Major shareholders and directors have committed to participate, while the offer excludes ineligible shareholders and related parties.